Joaquim Bellmunt, MD, PhD, on Bladder Cancer: The Future of Immunotherapies

2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Tweet this page

Joaquim Bellmunt, MD, PhD, of Dana-Farber Cancer Institute, discusses refining treatment choices with new combinations and sequencing strategies.

Advertisement

Advertisement



Jun
18
Today In Oncology
Eating a High-Quality Diet Could Decrease Cancer Survivors’ Risk of Death by 65%
Older Patients With Melanoma Fare Better on Anti–PD-1 Immunotherapy Than Younger Patients
Total Neoadjuvant Therapy for Borderline Resectable Pancreatic Adenocarcinoma
ASCO Guideline for Geriatric Oncology: Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy
FDA and EMA Accept Regulatory Submissions for Review of Talazoparib for Patients With Germline BRCA-Mutated Metastatic Breast Cancer
View More 
;
Advertisement
© 2018 HSP News Service, L.L.C.
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.